Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...
Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading Volume – Here’s What Happened
Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw strong trading volume on Friday . 413,080 shares were traded during trading, a decline of 47% from the previous session’s volume ...
pharmaphorum6d
Capricor files cell therapy for DMD cardiomyopathy with FDA
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...
Zacks.com on MSN6d
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
Pharmabiz5d
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...
Managed Healthcare Executive6d
Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...
Nasdaq6d
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application (BLA) to the FDA seeking full approval for deramiocel to ...